Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

• Control of myeloma was effective with bicistronic CAR T cells targeting BCMA and CD229, even with low BCMA expression.
• The study involved K562 tumor cell line clones, showing variability in CD229 expression gradient during experiments.
• Clonal assessment revealed the potential of dual targeting to enhance myeloma treatment outcomes despite BCMA limitations.
• Results imply a synergistic effect between BCMA and CD229 targeting in CAR T cell therapies for myeloma.